RIVIA’s Spark AI Accelerates Clinical Data Review: Accepted for Presentation at ESMO AI 2025

We’re proud to announce that RIVIA’s abstract, “Accelerating Clinical Data Review with AI: Evaluation of RIVIA’s Spark in a Phase 2 Trial,” has been accepted for presentation at ESMO AI 2025 in Berlin.

‍

This milestone marks a defining moment for how artificial intelligence is reshaping clinical research workflows — bringing real-time data exploration and autonomous interpretation directly into the hands of clinical teams.

Transforming Clinical Review with Generative AI

Clinical leaders and CMOs spend countless hours transforming raw clinical data into interpretable insights: summarizing patient narratives, generating safety reports, and tracking dose-response relationships. These tasks, while essential for safety oversight, regulatory readiness, and dose-response evaluation, have traditionally been repetitive and resource-intensive.

‍

RIVIA’s Spark AI Assistant changes that. Built for clinical data environments, Spark enables natural-language interaction with live trial datasets — allowing users to ask complex analytical questions like “Show me the trend in ALT values from baseline to week 12 for Cohort B” and instantly receive structured reasoning, visualizations, and data-validated summaries.

Quantifiable Impact: 91% Time Reduction

In a Phase 2 study evaluated between May and July 2025, the sponsor team used Spark to perform typical data review tasks, from adverse event correlation to patient cohort construction and narrative generation. The results were transformative:

• Average manual task time: 47 minutes
• Average Spark response time: 2 minutes
• Average time saved per task: 91%

‍

Over the course of the study, this translated into 20 hours of time saved — equivalent to 91% of the time effort the team would otherwise have spent answering the questions. This time was instead reallocated to higher-value clinical decisions rather than routine data manipulation.

Beyond Efficiency: Enabling Clinical Intelligence

The study demonstrated that Spark not only accelerates workflows but enhances clinical autonomy and insight discovery. Investigators were able to explore patient-level data directly, generate visual summaries, and identify clinically relevant trends without relying on data managers or programmers.

‍

By embedding generative AI directly into the clinical review process, Spark bridges the gap between data science and medical judgment — empowering sponsors to make faster, evidence-based decisions during ongoing trials.

A New Paradigm for AI in Clinical Development

The acceptance of this abstract at ESMO AI underscores a broader shift in the clinical research ecosystem: from retrospective data analysis to real-time, AI-driven decision support.
‍

RIVIA’s Spark is not just an assistant — it’s a collaborative intelligence layer that transforms how clinical teams interact with data, accelerating the path from insight to action.

‍

Presented at: ESMO AI 2025, Berlin.
‍